Abbott Buying VisioGen for $400 Million
Abbott (NYSE: ABT) has agreed to acquire Visiogen Inc., an Irvine, Calif.-based developer of products for cataract and refractive patients, for $400 million in cash. Viseogen had raised around $97 million in VC funding since 2001, from firms like Three Arch Partners, New Leaf Venture Partners, Novartis Venture Fund, Prospect Venture Partners, CMEA Capital, Technology Partners and Foundation Medical Partners.
3 September 2009•5 mins read
